LungLife AI Inc (LLAI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LungLife AI Inc (LLAI) has a cash flow conversion efficiency ratio of -0.245x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.94 Million ≈ $-236.53 USD) by net assets (GBX7.93 Million ≈ $965.22 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LungLife AI Inc - Cash Flow Conversion Efficiency Trend (2018–2023)
This chart illustrates how LungLife AI Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LungLife AI Inc (LLAI) financial obligations for a breakdown of total debt and financial obligations.
LungLife AI Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LungLife AI Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Endor AG
MU:E2N
|
691.016x |
|
ECD Automotive Design Inc
NASDAQ:ECDA
|
0.126x |
|
Worldsec Ltd
LSE:WSL
|
-0.052x |
|
Nostra Terra Oil and Gas Company PLC
LSE:NTOG
|
0.205x |
|
Regal Partners Global Investments Limited
AU:RG1
|
0.038x |
|
Airports of Thailand Public Company Limited
F:TX3A
|
0.056x |
|
Quaser Machine Tools
TWO:4563
|
0.130x |
|
Ordinary Fully Paid Deferred Settlement
AU:BCNDA
|
0.080x |
Annual Cash Flow Conversion Efficiency for LungLife AI Inc (2018–2023)
The table below shows the annual cash flow conversion efficiency of LungLife AI Inc from 2018 to 2023. For the full company profile with market capitalisation and key ratios, see market cap of LungLife AI Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | GBX7.91 Million ≈ $962.78 |
GBX-5.02 Million ≈ $-610.79 |
-0.634x | -42.62% |
| 2022-12-31 | GBX13.14 Million ≈ $1.60K |
GBX-5.84 Million ≈ $-711.17 |
-0.445x | -18.78% |
| 2021-12-31 | GBX20.13 Million ≈ $2.45K |
GBX-7.54 Million ≈ $-917.26 |
-0.375x | -154.46% |
| 2020-12-31 | GBX19.53 Million ≈ $2.38K |
GBX-2.87 Million ≈ $-349.69 |
-0.147x | -130.12% |
| 2019-12-31 | GBX-6.80 Million ≈ $-827.11 |
GBX-3.32 Million ≈ $-404.19 |
0.489x | -29.30% |
| 2018-12-31 | GBX-3.10 Million ≈ $-377.22 |
GBX-2.14 Million ≈ $-260.72 |
0.691x | -- |
About LungLife AI Inc
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more